U.S. markets closed
  • S&P Futures

    4,433.25
    +0.25 (+0.01%)
     
  • Dow Futures

    34,783.00
    +40.00 (+0.12%)
     
  • Nasdaq Futures

    15,167.00
    -27.75 (-0.18%)
     
  • Russell 2000 Futures

    2,282.10
    +5.10 (+0.22%)
     
  • Crude Oil

    76.17
    +0.72 (+0.95%)
     
  • Gold

    1,749.70
    -2.30 (-0.13%)
     
  • Silver

    22.61
    -0.08 (-0.35%)
     
  • EUR/USD

    1.1696
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    1.4840
    +0.0240 (+1.64%)
     
  • Vix

    18.76
    +1.01 (+5.69%)
     
  • GBP/USD

    1.3705
    +0.0001 (+0.01%)
     
  • USD/JPY

    111.2200
    +0.2420 (+0.22%)
     
  • BTC-USD

    42,588.65
    -1,423.61 (-3.23%)
     
  • CMC Crypto 200

    1,054.95
    -46.57 (-4.23%)
     
  • FTSE 100

    7,063.40
    +11.92 (+0.17%)
     
  • Nikkei 225

    30,134.53
    -105.53 (-0.35%)
     

SHAREHOLDER ALERT: ATER PRVB FREQ: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / July 6, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Aterian, Inc. (NASDAQ:ATER)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/aterian-inc-loss-submission-form?prid=17421&wire=1
Lead Plaintiff Deadline: July 12, 2021
Class Period: December 1, 2020 - May 3, 2021

Allegations against ATER include that: (i) the Company's organic growth is plummeting; (ii) the Company's recent, self-lauded acquisitions were overpayments for flawed assets from questionable sources; (iii) Aterian's purported artificial intelligence software is a flawed product that lacks customer interest; (iv) Aterian uses rebate programs and paid or artificial reviews to pump up their product offerings; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Provention Bio, Inc. (NASDAQ:PRVB)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/provention-bio-inc-loss-submission-form?prid=17421&wire=1
Lead Plaintiff Deadline: July 20, 2021
Class Period: November 2, 2020 - April 8, 2021

Allegations against PRVB include that: (i) the teplizumab Biologics License Application ("BLA") was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Frequency Therapeutics, Inc. (NASDAQ:FREQ)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=17421&wire=1
Lead Plaintiff Deadline: August 2, 2021
Class Period: November 16, 2020 - March 22, 2021

Allegations against FREQ include that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong



View source version on accesswire.com:
https://www.accesswire.com/654384/SHAREHOLDER-ALERT-ATER-PRVB-FREQ-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines